Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial

被引：2
|
作者：
Sockel, Katja [1 ]
Greiner, Jochen [2 ]
Trenschel, Rudolf [3 ]
Unzicker, Christian [4 ]
Kobbe, Guido [5 ]
Finke, Jurgen [6 ]
Germing, Ulrich [7 ]
Mohr, Brigitte [1 ]
Beelen, Dietrich [8 ]
Ehninger, Gerhard [9 ]
Bornhaeuser, Martin [1 ]
Platzbecker, Uwe [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
[3] Univ Hosp, Clin Bone Marrow Transplantat, Essen, Germany
[4] Wuerzburg Univ, Med Ctr, Dept Internal Med 2, Wurzburg, Germany
[5] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[6] Univ Freiburg Klinikum, Dept Med 1, Freiburg, Germany
[7] Univ Hosp Dusseldorf, Dusseldorf, Germany
[8] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany
[9] Univ Hosp Carl Gustav Carus, Med Clin & Policlin 1, D-01307 Dresden, Germany
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3060.3060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1320 / 1320
页数：1
相关论文
共 50 条
  • [31] Panobinostat as maintenance therapy after allogeneic stem cell transplantation in patients with high-risk MDS or AML: Results from the dose-escalation part of the PANOBEST trial
    Bug, G.
    Burchert, A.
    Wagner, E. M.
    Kroeger, N.
    Jedlickova, Z.
    Gueller, S.
    Wolf, A.
    Huenecke, S.
    Bader, P.
    Serve, H.
    Ottmann, O. G.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S59 - S59
  • [32] IN VIVO TREATMENT BY LENALIDOMIDE CHANGES THE CLONAL EVOLUTION OF HEMATOPOIETIC STEM PROGENITOR CELLS OF NON DEL(5Q) LOW RISK MDS PATIENTS
    Chesnais, V.
    Renneville, A.
    Toma, A.
    Passet, M.
    Gauthier, A.
    Lefevre, A.
    Delaunay, J.
    Rose, C.
    Stamatoullas, A.
    Beyne-Rauzy, O.
    Fenaux, P.
    Dreyfus, F.
    Preudhomme, C.
    Fontenay, M.
    Kosmider, O.
    HAEMATOLOGICA, 2015, 100 : 16 - 16
  • [33] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (vol 28, pg 1033, 2014)
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2015, 29 (12) : 2452 - 2452
  • [34] Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BLOOD, 2019, 134
  • [35] Maintenance 5-Azactidine May Improve Outcomes after Allogeneic Stem-Cell Transplantation in High-Risk AML and MDS Patients
    Danylesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S179 - S180
  • [36] Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
    Toribio Castello, Sofia M.
    Lopez-Cadenas, Felix
    Preudhomme, Claude
    Villaverde Ramiro, Angela
    Fenwarth, Laurene
    Lumbreras, Eva
    Gonzalez, Teresa
    Del Rey, Monica
    Xicoy, Blanca
    Renneville, Aline
    Sanchez-Garcia, Joaquin
    Coll, Rosa
    Slama, Bohrane
    Angel Hernandez-Rivas, Jose
    Thepot, Sylvain
    Bernal, Teresa
    Guerci-Bresler, Agnes
    Gotze, Katharina
    Maria Hernandez-Rivas, Jesus
    Fenaux, Pierre
    Del Canizo, Consuelo
    Diez-Campelo, Maria
    BLOOD, 2022, 140 : 9740 - 9743
  • [37] Treatment of lower risk MDS with del 5q by lenalidomide (LEN), with or without G-CSF: current results of the French Patient Named Program (ATU)
    Sebert, M.
    Le Bras, F.
    Lamy, T.
    Dreyfus, F.
    Bannos, A.
    Blanc, M.
    Vey, N.
    Gardembas, M.
    Baudurer, F.
    Turlure, P.
    Beyne-Rauzy, O.
    Guercy, A.
    Fenaux, P.
    Ades, L.
    LEUKEMIA RESEARCH, 2009, 33 : S125 - S126
  • [38] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
  • [39] Minimal Residual Disease (MRD) Based Preemptive 5-Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT - Results of the "RELAZA" Trial
    Platzbecker, Uwe
    Wermke, Martin
    Radke, Joergen
    Kiani, Alexander
    Seltmann, Franzi
    Roellig, Christoph
    von Bonin, Malte
    Mohr, Brigitte
    Oelschlaegel, Uta
    Schetelig, Johannes
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Thiede, Christian
    BLOOD, 2010, 116 (21) : 298 - 299
  • [40] 5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS
    Puglisi, Bruna
    Saraceni, Francesco
    Guerzoni, Selene
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Lotito, Antonio
    Colaneri, Francesca Romana
    Federici, Irene
    Olivieri, Attilio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 364 - 365
12345